TenNor Therapeutics, a Suzhou, China-based clinical stage company focused on the development of dual-acting antibiotics, raised $25m in Series B financing.
The round was led by Northern Light Venture Capital with participation from current investors Frontline BioVentures, WuXi PharmaTech Healthcare Fund I, Oriza Venture Capital and Relativity Healthcare Fund.
The company intends to use the funds to advance TNP-2092 oral capsule into Phase III clinical trials, as well as a second product into the clinical proof-of-concept stage and a third product into Phase I of clinical development.
Established in 2013 in BioBAY, a life science park based in Suzhou, China, by Dr. Zhenkun Ma, CEO, TenNor is advancing several dual-acting molecules through its preclinical and clinical development pipeline. The most advanced product, TNP-2092 oral capsule, is a locally acting gastrointestinal tract antibiotic having the potential to improve the treatment of digestive diseases associated with Helicobacter pylori and other gastrointestinal bacterial infections.
The compound is currently in the early-stage of clinical development.
The company has acquired patents and other assets from Cumbre IP Venture and patents from the TB Alliance.